Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics announced the publication of its pivotal Phase 3 trial data for aglatimagene besadenovec in The Lancet Oncology, demonstrating a 30% improvement in disease-free survival for patients with localized prostate cancer. The peer-reviewed data confirms a statistically significant hazard ratio of 0.70 (p=0.016) and a 38% improvement in prostate cancer-specific DFS, supporting the company's plan to submit a Biologics License Application in the fourth quarter of 2026.
Key figures
- Drug Name
- aglatimagene besadenovec (CAN-2409)
- Phase Of Trial
- Phase 3
- Dfs p value
- 0.016
- Dfs improvement
- 30%
- Dfs hazard ratio
- 0.7
- Patient enrollment
- 745
- Median follow up months
- 58
- Prostate specific dfs p value
- 0.0046
- Prostate specific dfs improvement
- 38%
- Prostate specific dfs hazard ratio
- 0.62
- Pathological complete response p value
- 0.0018
- Pathological complete response placebo
- 63%
- Updated prostate specific dfs improvement
- 39%
- Pathological complete response aglatimagene
- 80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.